Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
about
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaReview of health-related quality of life data in multiple myeloma patients treated with novel agents.Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIMChallenges in multiple myeloma diagnosis and treatment.Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.New approaches to management of multiple myeloma.Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study.Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment.Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups.Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.
P2860
Q26992002-8D3647FC-CB58-4C56-A7AA-CC0C83479122Q30650394-FA14C38E-36C1-4868-B006-B9B23420F34CQ33404749-E2F416E9-4E60-48D9-AEBE-F90D98BBE60BQ35996498-1C1F074A-CE9A-449E-BBAB-94029FD562AAQ36852225-7A65E58B-085A-4D99-AE95-0709C7E68C0DQ36907828-E9175D42-4CFC-49D3-8C8C-E33ACDE8BFDEQ37146672-37B8A1B7-6ECF-4ED4-8727-18046B7D24DAQ38146900-BE218CEF-C1F1-4976-AC7D-DC2BA64CB069Q38191867-509DFCF7-CA6D-4B4A-9CAE-2E2866D393DAQ38367654-0141E0EB-46F1-474E-B052-C4EF03553097Q38695071-BA39DBCD-22E9-4A82-80B7-AB9579E1C4C2Q40386543-94FD81FC-B531-42BC-8C2D-B13A5FAB1045Q40511222-E34EE718-AF90-4C19-8F76-3ED77BF226E4Q47572205-91E0B774-C9AF-4123-AF3C-8F75CFB5395BQ48056468-6EF4E58D-2E4B-4E83-90C0-316BABE67BD6Q48084283-3EABD686-26D9-46D2-A8EA-ACC4F67FE238Q50048714-7A1802BE-96C3-42AE-B9DF-645C57C2A475Q53098336-E34FFDEC-85E9-4282-9D2B-911CD0906E8CQ54772546-F9996310-9FBB-4B7E-A55A-B2D1B2B5C374
P2860
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Practical management of advers ...... attenuated in older patients?
@ast
Practical management of advers ...... attenuated in older patients?
@en
type
label
Practical management of advers ...... attenuated in older patients?
@ast
Practical management of advers ...... attenuated in older patients?
@en
prefLabel
Practical management of advers ...... attenuated in older patients?
@ast
Practical management of advers ...... attenuated in older patients?
@en
P1433
P1476
Practical management of advers ...... attenuated in older patients?
@en
P2093
Maria-Victoria Mateos
Sara Bringhen
P304
P356
10.1016/J.BLRE.2011.03.005
P577
2011-04-16T00:00:00Z